Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
VRTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $128.16B
- P/E (TTM)
- 29.45
- Forward P/E
- 25.15
- EPS (TTM)
- $17.17
- Dividend yield
- None
- 52-week range
- 402.58 – 560.25
- Day range
- 503.94 – 511.47
- Volume / Avg
- 806.60K / 1.16M
- Beta
- —
- Shares outstanding
- 253.46M
- Next earnings
- Nov 2, 2026
52-week range
VRTX stock today
Shares of Vertex Pharmaceuticals (VRTX) finished higher on Oct 7 at $505.64, a gain of 0.66% or $3.33 per share, versus the S&P 500's 0.22% decline. At this level, VRTX sits in the middle of its 52-week range of $402.58 to $560.25: 9.7% below the high, set on Sep 3, 2026 and 25.6% above the low. VRTX is up 11.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 23.2%.
At 29.4x trailing earnings, Vertex Pharmaceuticals trades above the peer-group median of 18.4x. Its forward P/E of 25.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Vertex Pharmaceuticals's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Vertex Pharmaceuticals
Company profileVertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Reshma Kewalramani FASN, M.D.
- Headquarters
- Boston, MA
- Employees
- 6,400
- IPO year
- 1991
- Website
- vrtx.com
Financial highlights
Full financialsIn fiscal 2025, Vertex Pharmaceuticals generated $12.00 billion in revenue, up 8.9% from fiscal 2024, its 11th consecutive year of revenue growth. Net income was $3.95 billion, for a net margin of 32.9% versus a median of 36.7% in the prior 5 years. Gross margin was 86.2% (up from 86.1%) and operating margin 34.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B |
| Growth | +8.90% | +11.66% | +10.51% | +17.91% | +22.06% |
| Net income | $3.95B | $-535.60M | $3.62B | $3.32B | $2.34B |
| EPS (diluted) | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 |
Analyst forecast
ForecastConsensus (32 analysts)
buy
Avg. price target
$571.39+13.00%
- Strong buy 6
- Buy 20
- Hold 5
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $4.30
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $4.31 vs —
VRTX news
All VRTX news- Vertex to Announce Third Quarter 2026 Financial Results November 2ndBusiness Wire
- Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?NasdaqNVAX, VRTX
- Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowNasdaq
- Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?NasdaqAMGN, VRTX
- Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to KnowNasdaq
- Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?NasdaqAXSM, VRTX
- Capital Group Global Growth Equity ETF Experiences Big OutflowNasdaqCGGO, WDC, VRTX, SWKS
- Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A DowngradeSeeking Alpha
Vertex Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BMYBristol-Myers Squibb Company | 59.70 | +0.18% | $121.95B | vs VRTX |
| SNYSanofi ADS | 40.20 | +1.62% | $96.32B | vs VRTX |
| PFEPfizer Inc. | 28.00 | +1.82% | $159.59B | vs VRTX |
| GSKGSK plc ADR | 47.02 | +0.90% | $94.21B | vs VRTX |
| NVONovo Nordisk A/S | 38.26 | +1.95% | $168.89B | vs VRTX |
| ABTAbbott Laboratories | 98.73 | +0.58% | $170.84B | vs VRTX |
| REGNRegeneron Pharmaceuticals Inc. | 742.12 | +0.46% | $76.40B | vs VRTX |
| TAKTakeda Pharmaceutical Company Limited ADR | 18.37 | +1.49% | $58.68B | vs VRTX |
Indexes, lists and sector
Index membership
Vertex Pharmaceuticals stock FAQ
What is Vertex Pharmaceuticals's stock price today?
VRTX last traded at $505.64 as of Oct 7, 4:00 PM EDT, up 0.66% on the day. Prices are delayed at least 15 minutes.
Does Vertex Pharmaceuticals pay a dividend?
No. Vertex Pharmaceuticals does not currently pay a regular cash dividend.
When is Vertex Pharmaceuticals's next earnings date?
Vertex Pharmaceuticals is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $4.30.
What is VRTX's P/E ratio?
VRTX trades at a trailing P/E ratio of 29.45 and a forward P/E of 25.15, compared with a median of 18.4 for its closest peers.
Is Vertex Pharmaceuticals in the S&P 500?
Yes. Vertex Pharmaceuticals (VRTX) is a constituent of the S&P 500 index.
Who is Vertex Pharmaceuticals's CEO?
Dr. Reshma Kewalramani FASN, M.D. is the chief executive officer of Vertex Pharmaceuticals Incorporated, which has about 6,400 employees.
Has VRTX ever split its stock?
Yes. The most recent VRTX stock split was a 2-for-1 split on Aug 24, 2000.